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Abstract. Angiogenic therapy is considered to be a promising tool for treatment of ischemic diseases. Many in vivo and in vitro
assays have been developed to identify potential proangiogenic drugs and to investigate their mode of action. However, until now
no validated system exists that would allow quantitation of angiogenesis in vitro in only one assay. Here, a previously established
all-in-one in vitro assay based on staging of the angiogenic cascade was validated by quantitation of the effects of the known
proangiogenic factors VEGF-A and FGF-2. Both growth factors were applied separately or in combination to human endothelial
cell cultures derived from the heart and the foreskin, and angiogenesis was quantitated over 30 days of culture. Additionally,
gene expression of VEGFR-1, VEGFR-2 and FGFR-1 at 3, 10, 20 or 40 days of cultivation was quantitated by RT-qPCR. In both
cultures, VEGF-A as well as FGF-2 induced a run through all defined stages of angiogenesis in vitro. Application of VEGF-A
only led to formation of irregular globular endothelial structures, while FGF-2 resulted in development of regular capillary-like
structures. Quantitation of the angiogenic effects of VEGF-A and transcripts of VEGFR-1 and VEGFR-2 showed that a high
VEGFR-1/VEGFR-2 ratio evoked deceleration of angiogenesis.
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1. Introduction
Angiogenesis, i.e. the sprouting of vessels from pre-existing ones, and its inhibition, antiangiogenesis,
are involved in a variety of diseases. Both, the therapeutic use of antiangiogenic drugs for treatment of
cancer as well as application of proangiogenic substances to improve perfusion of ischemic tissues gain in
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importance in modern medicine [10, 43]. To date numerous pro- and antiangiogenic substances have been
identified or developed and their molecular effects on endothelial cells have been studied exhaustively
[32]. These factors interfere with the steps of the angiogenic cascade, i.e. degradation of the basal lamina,
migration and proliferation of endothelial cells, lumenisation of new sprouts and endothelial secretion of
basal lamina components to stabilise the newly formed vessels [2, 8]. Since we and others have shown
that successful manipulation of angiogenesis or antiangiogenesis depends on drugs, interfering with all
steps of angiogenesis, it is indispensable to determine precisely the steps in which pro- or antiangiogenic
substances influence the angiogenic cascade [4, 11, 23, 42]. These investigations on angiogenesis and
antiangiogenesis are primarily performed in vitro. Therefore, different in vitro assays of angiogenesis
are available, and all of them are based on only one specific, single step of the angiogenic cascade [2,
5]. However, the extrapolation of observed effects within in vivo experiments or even in clinical trials
frequently lead to disappointing results in preclinical and clinical application [20].
Supposing that this might be due to the lack of comparability of the different angiogenesis assays, this
study was performed to verify the effects of known proangiogenic factors with a previously established
method, that allows investigation and quantitation of all steps of the angiogenic cascade in one single
assay [3, 4], applying two different human endothelial cell cultures.
Therefore, Vascular Endothelial Growth Factor A (VEGF-A) and Fibroblast Growth Factor 2 (FGF-2)
were chosen, as their effects have been extensively investigated in vivo as well as in vitro and they are
considered to be the most potent stimulators of angiogenesis [16, 33].
The VEGF family includes several proteins, i.e. VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and
Placenta Growth Factor (PlGF). Within this family VEGF-A is the most potent stimulator of angiogenesis
[21]. Seven proangiogenic isoforms of VEGF-A (VEGF-A121, VEGF-A145, VEGF-A162, VEGF-A165,
VEGF-A183, VEGF-A189, VEGF-A206) are known to arise from alternative splicing. These variants all
display the same biological activity, but they differ in their capacity to bind to heparin and the extracellular
matrix. VEGF-A165 is the predominant splice variant, and it is usually designated as VEGF-A. VEGF-A
acts via two different blood vessel endothelial receptors, i.e. VEGFR-1 (fms-like tyrosine kinase) and
VEGFR-2 (fetal liver kinase 1/kinase domain region), while VEGFR-3 is largely restricted to lymphatic
endothelial cells [21, 24, 25, 30].
FGF-2 (also known as basic FGF) is a member of a large family of structurally homologous, functionally
distinct small polypeptides, which are potent regulators of cell growth and differentiation in a variety
of cell types [33]. Only FGF-1 and FGF-2 are expressed at high levels in the adult organism. While
expression of FGF-1 is primarily constricted to the central nervous system, FGF-2 is expressed throughout
all tissues and cells including endothelial cells [36]. FGF-2 exerts its effects by interaction with both cell
surface receptor tyrosine kinases (FGFR1–4) and extracellular and cell-surface-bound heparan sulphate
proteoglycans (HSPGs). FGFRs mediate the effects of FGF-2 on cells, whereas the more general role
of HSPGs is the modulation of FGF-2 binding to its receptors. FGFR1 and FGFR2 are expressed on
endothelial cells, but FGFR1 is more abundant [39]. The cellular effect of FGF-2 via FGFR-1 consists in
the release of urinary plasminogen activator and collagenase in endothelial cells, enabling their migration.
Additionally, FGF-2 acts as a chemoattractant for endothelial cells also effecting their migration [1].
The aim of this study was to investigate, whether the previously established all-in-one in vitro angiogen-
esis assay could be used to confirm and quantitate the proangiogenic effects of VEGF-A and FGF-2 in two
different human microvascular endothelial cell cultures in the course of method validation. Additionally,
for evaluation of the effects of VEGF-A and FGF-2, the gene expression of their blood vessel endothelial
cell specific receptors, i.e. VEGFR-1, VEGFR-2 and FGFR-1, was measured during cultivation in both
cell types.
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2. Materials and methods
2.1. Human endothelial cells and media
Human microvascular endothelial cells derived either from the heart muscle of a 54 year old female
(HCMEC), or from the neonatal foreskin (HDMEC) were purchased from Lonza Biosciences (Verviers,
Belgium; original catalogue cell culture names: HMVEC-C Cardiac MV Endo Cells and HMVEC-
dBlNeo, respectively).
A basic medium (BM) serving as negative control was constituted by using the growth medium provided
by the distributors (EBM-2/EGM-2 MV, Lonza Bioscience, Verviers, Belgium) without growth factors
and with only 2% of the provided serum. This medium composition turned out to retain cell survival but
did not result in any angiogenic response of cells.
For positive controls the provided growth medium was used as suggested by the distributors (positive
medium, PM). This medium consisted of a mixture of several growth factors including Epidermal Growth
Factor (EGF), Insulin-like Growth Factor 1 (IGF-1), hydrocortisone and some less specified components
such as Bovine Brain Extract and Fetal Bovine Serum in addition to VEGF-A and FGF-2. Preliminary
works in our laboratory showed that this medium stimulates endothelial cells to run through all phases
of the angiogenic cascade in vitro within 30–40 days.
2.2. Growth factors
The growth factors VEGF-A (human, recombinant antigen; Strathmann Biotec, Hamburg, Germany)
and/or FGF-2 (human, recombinant antigen; Strathmann Biotec, Hamburg, Germany) were added to the
basic medium. Concentrations of VEGF-A and FGF-2 were determined according to Cavallaro et al. [13],
who used these factors at a concentration of 10 ng/ml. In a pilot study performed in our laboratory, the
effects of both growth factors were tested at concentrations of 5 ng/ml, 10 ng/ml and 20 ng/ml. Results
showed that no angiogenic effect of VEGF-A or FGF-2 could be observed at a concentration of 5 ng/ml.
However, when concentrations of 10 or 20 ng/ml were used, similar angiogenic effects were recorded
(unpublished data). Therefore, the concentration of 10 ng/ml of each growth factor was chosen for this
study.
2.3. In vitro angiogenesis assay
Endothelial cells seeded in gelatine-coated 24-well plates (Iwaki, Tokyo, Japan) at a concentration of
4.1–4.5 × 104 cells per well were cultivated for 30 days.
Phase-contrast microscopy was carried out daily applying an inverted microscope (Axiovert 25; Zeiss,
Jena, Germany). Digital pictures were taken with a video camera (Inteq 000610; Inteq, Berlin, Germany)
and the image editing system Axiovision (Version 3.0; Zeiss, Jena, Germany).
Quantitation of angiogenesis was carried out by the previously established method [3, 4]. In brief, cells
were incubated in the proangiogenic medium and the changes of endothelial cell morphology observed
in the course of the angiogenic cascade in vitro were classified as six defined stages (Table 1). On the first
day of investigation, visual fields were chosen randomly and defined per coordinates. Thenceforward,
these visual fields were photographed every second day (investigation days). The obtained cell images
were assigned to the respective stage of angiogenesis. For each visual field the time-dependent course of
angiogenesis was investigated by calculating the sum of assigned stages of angiogenesis in vitro during
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Table 1
Definition of stages of angiogenesis in vitro and description of cell morphology within the different stages
Stage no. Morphology of endothelial cells
Stage 1 Confluent monolayer
Polygonal shaped cells
Stage 2 Endothelial sprouting, late phase
>50% elongated shaped cells
Stage 3 Linear side by side arrangement, late phase
>50% linearly arranged cells
Stage 4 Networking
Network of linearly arranged cells
Stage 5 Three-dimensional organisation, early phase
Appearance of capillary-like structures (linear structures of endothelial cells with
a diameter of more than 28m; for these structures an internal lumen was shown
by electron microscopy)
Stage 6 Three-dimensional organisation, late phase
All linearly arranged cells form capillary-like structures; dissolution of the cell layer
on the bottom
all investigation days. Extensive validation of this method showed that representative quantitation can be
carried out in 4 wells and 4 visual fields per well.
Quantitation of angiogenesis induced by VEGF-A and FGF-2 was carried out as follows: A negative
control was cultivated in BM, and three experiment groups were cultivated in BM supplemented with
VEGF-A, FGF-2 as well as VEGF-A and FGF-2, respectively. Cells were also incubated in PM as positive
controls; their run through the stages of angiogenesis provided a standard curve, characteristic for each
cell culture. The documentation of the visual fields was performed over 30 days, every second day (15
investigation days) as described above. Two visual fields were chosen from the border area and 2 visual
fields from the centre of the culture well. For each visual field, the sum of assigned stages at the 15
investigation days (S) was calculated. The proangiogenic effects of VEGF-A, FGF-2 or VEGF-A and
FGF-2 were determined by calculating the ratio of the arithmetic mean of the sums of the 16 visual fields
of each approach (Sgrowthfactorj ; j = 1, . . . , 16) and the arithmetic mean of the sums of the 16 visual fields
derived from the cells incubated in PM (SPMj ; j = 1, . . . , 16).
Analysis of variance (ANOVA) and a post-hoc Tukey-HSD test was performed on the obtained data
using the STATISTICA Vers. 6.0 software (StatSoft, Tulsa, OK, USA) to determine the differences
between treatments (p < 0.05).
2.4. Quantitative analysis of VEGFR-1, VEGFR-2 and FGFR-1 transcripts by RT-qPCR
Cells were harvested on the 3rd, 10th, 20th or 40th day of cultivation. Total RNA was isolated from
the cells using the Invisorb Spin Cell RNA Mini Kit (Invitek, Berlin, Germany). The isolated RNA
was reverse transcribed with the First Strand cDNA Synthesis Kit (K1612, Fermenta, St. Leon-Rot,
Germany). Quantitative PCR was performed with the Rotor Gene 6000 (Corbett, Wasserburg, Germany)
using MaximaTM SYBR Green/Fluorescein qPCR Master Mix (2X) (Fermentas, St. Leon-Rot, Germany).
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All samples were run in duplicate and each run included a serial dilution of a cDNA mix of all the
samples to obtain a standard curve for each gene. Gene specific primers (Table 2) were either selected
from literature or designed using RTprimerDB [26]. Analysis of gene expression with quantitative PCR
(qPCR) requires the knowledge of the amount of starting material in each sample. This estimation is
best performed through normalisation with multiple reference genes [40]. In this survey, 10 reference
genes were initially tested between the different samples as to identify the most stable reference genes
(Table 2), which could then be used for the further normalisation. Using the GeNorm software [40],
4 reference genes were identified for the calculation of the sample specific normalisation factors (from
most stable to less stable: GAPDH, UBC, TBP and HPRT). Normalized relative quantities of the mRNA
coding for VEGFR-1, VEGFR-2 and FGFR-1 were calculated using REST [31] and qBase [22] with
Table 2
List of primers, used for RT-qPCR. Genes of interest: FGFR1, VEGFR-1 and VEGFR-2; reference genes: Actin, beta (ACTB),
beta-2-microglobulin (B2M), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase (HMBS),
hypoxanthine phosphoribosyltransferase 1 (HPRT1), ribosomal protein L13 (RPL13), succinate dehydrogenase complex, subunit
A (SDHA), tyrosine 3-monooxygenase/tryptophan 5-monooxygenas (YWHAZ), TATA box binding protein (TBP), ubiquitin C
(UBC)
Gene Orientation Primer sequence (5′–3′) Amplicon Annealing GenBank accession
length temperature no. or reference
(bp) (◦C)
VEGFR-1 Forward GACCTGGAGTTACCCTGATGAAA 76 60 NM 002019
Reverse GGCATGGGAATTGCTTTGG
VEGFR-2 Forward CACCACTCAAACGCTGACATGTA 95 60 Sussman et al. [35]
Reverse GCTCGTTGGCGCACTCTT
FGFR1 Forward CCTCTATGTGGGCATGGTTT 131 60 NM 015850
Reverse TACAGGAAGGACGATCTGGG
ACTB Forward CCTGGCACCCAGCACAAT 145 60 Sussman et al. [35]
Reverse GGGCCGGACTCGTCATACT
B2M Forward ATGAGTATGCCTGCCGTGTG 101 60 Murphy et al. [28]
Reverse GGCATCTTCAAACCTCCATG
GAPDH Forward GCAAATTCCATGGCACCGT 104 60 NM 002046
Reverse GCCCCACTTG TTTTGGAGG
HMBS Forward ACCAAGGAGCTTGAACATGC 145 60 Steckelbroeck et al. [34]
Reverse GAAAGACAACAGCATCATGAG
HPRT1 Forward AATTATGGACAGGACTGAACGTCTTGCT 114 60 Baudry et al. [6]
Reverse TCCAGCAGGTCAGCAAAGAATTTATAGC
RPL13 Forward CCCGTCCGGAACGTCTATAA 77 60 NM 000977
Reverse CTAGCGAAGGCTTTGAAATTCTTC
SDHA Forward TGGGAACAAGAGGGCATCTG 86 60 Vandesompele et al. [40]
Reverse CCACCACTGCATCAAATTCATG
YWHAZ Forward ACTTTTGGTACATTGTGGCTTCAA 94 60 Vandesompele et al. [40]
Reverse CCGCCAGGACAAACCAGTAT
TBP Forward TGCACAGGAGCCAAGAGTGAA 133 60 Dallol et al. [14]
Reverse CACATCACAGCTCCCCACCA
UBC Forward ATTTGGGTCGCGGTTCTTG 132 60 Vandesompele et al. [40]
Reverse TGCCTTGACATTCTCGATGGT
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the selected set of reference genes. The REST software analyses if gene-expression is significantly
different between two sample groups using bootstrap randomisation [31]. The qBase software calculates
normalised relative expression quantities which can then be further used for statistical analysis. The
differences in the expression of the investigated genes (p < 0.05) were calculated by applying the t-test
implemented in Sigmaplot (Systat, Erkrath, Germany).
3. Results
3.1. Morphology of endothelial structures in course of angiogenesis in vitro induced by VEGF-A
and FGF-2
Cells incubated in BM showed a polygonal shape (stage 1) during the whole investigation period and
served as negative controls. Cells incubated in PM were confirmed to serve as positive controls as they
ran chronologically through the defined stages of angiogenesis in vitro during the investigation period of
30 days.
Fig. 1. Angiogenesis in vitro in human cardiac microvascular endothelial cells (HCMEC) cultivated in a basal medium supple-
mented with either FGF-2 (a–c) or VEGF-A (d–f), or both FGF-2 and VEGF-1 (h, i). Linear positioning of the cells in early
stages 2–3 (a, d, g) was followed by forming of a network in stage 4 (b, e, h) and regular strand-like (c, i) or irregular globular
structures (f) in stages 5–6. Bars: 50m.
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In HDMEC as well as in HCMEC effects on morphology were similar for each medium. The only
difference consisted in the characteristic and in principle lower cell density of HCMEC displayed by an
always discontinuous cell layer (Figs 1 and 2).
In all cultures, more than 50% of cells showed an elongated shape within 2–4 days (stage 2; Figs 1a,
d, g and 2a, d, g). The following characteristic morphological changes of endothelial cells perform-
ing angiogenesis in vitro were observable in all specimens at the latest after 18 days, as stated in
Table 1: linear arrangement of elongated cells (stage 3) and the formation of an endothelial network
(stage 4; Figs 1b, e, h and 2b, e, h). Except for HCMEC cultured in PM, all cultures reached the
final stages 5–6 within the investigation period of 30 days (Figs 1c, f, i and 2c, f, i). The three-
dimensional endothelial structures that appeared in stage 5–6 displayed continuously strand-like structures
in HCMEC and HDMEC incubated in PM, FGF-2 or VEGF-A and FGF-2 (Figs 1c, i and 2c, i).
Application of VEGF-A only resulted in the development of primarily irregular globular endothelial
structures with variable diameters of approximately 30–50m. These globular structures were always
attached to a fine network of very thin strand-like structures with diameters of at most 10m (Figs 1f
and 2f).
Fig. 2. Angiogenesis in vitro in human dermal microvascular endothelial cells (HDMEC) cultivated in a basal medium supple-
mented with either FGF-2 (a–c) or VEGF-A (d–f), or both FGF-2 and VEGF-A (h, i). Linear positioning of the cells in early
stages 2–3 (a, d, g) was followed by forming of a network in stage 4 (b, e, h) and regular strand-like (c, i) or irregular globular
structures (f) in stages 5–6. Bars: 50m.
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Fig. 3. Stages of angiogenesis in vitro of human cardiac microvascular endothelial cells (HCMEC) cultivated in a positive
medium (PM), a basal medium supplemented with either FGF-2, or VEGF-A or with both FGF-2 and VEGF-A recorded for
4 visual fields in 4 wells per culture during 30 days, every second day. Mean values per culture with SD are presented. The
stages of angiogenesis in vitro of cells incubated in PM differed to cells incubated in VEGF-A, FGF-2, VEGF-A and FGF-2
on day 4. The stages of angiogenesis in vitro of cells incubated in FGF-2 differed to the other specimens starting from day 6,
with exception for days 10–16 (not to PM). The stages of angiogenesis in vitro of cells incubated in PM differed to the other
specimens starting from day 18.
The time-dependent courses of the morphologically assigned stages of angiogenesis in HCMEC
and HDMEC cultured in PM or BM in the presence of VEGF-A, FGF-2 or VEFG-A and FGF-2 are
demonstrated in Figs 3 and 4.
Fig. 4. Stages of angiogenesis in vitro of human dermal microvascular endothelial cells (HDMEC) cultivated in a positive
medium (PM), a basal medium supplemented with either FGF-2, or VEGF-A or with both VEGF-A and FGF-2 recorded for 4
visual fields in 4 wells per culture during 30 days, every second day. Mean values per culture with SD are presented. The stages
of angiogenesis in vitro of cells incubated in PM differed to cells incubated in VEGF-A, FGF-2, VEGF-A and FGF-2 on day 4
and 6. The stages of angiogenesis in vitro of cells incubated in VEGF-A and FGF-2 differed to cells incubated in VEGF-A or
FGF-2 from day 4 to 8.
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3.2. Quantitation of angiogenesis in vitro induced by VEGF-A and FGF-2
The cells incubated in BM remained in stage 1 of angiogenesis in vitro throughout the study. As a
consequence these served as negative control, and were omitted from the statistical analysis.
Incubation of endothelial cells in PM led to a chronological run through all stages of angiogenesis.
Therefore, endothelial cells incubated in PM served as positive control and the sum of assigned stages of
angiogenesis in these cultures (SPMj ) was used for evaluation of the angiogenic potential of the cultures
incubated in VEGF-A, FGF-2 or VEGF-A and FGF-2.
The sum of assigned stages of angiogenesis obtained by the HCMEC cultivated in the presence of
VEGF-A was SVEGF−Aj = 66.2, higher than for PM (SPMj = 53.8) and for FGF-2, where it reached
SFGF−2j = 59.6 (p < 0.001). The incubation in the presence of both factors resulted in SVEGF−A+FGF−2j =
68.1, higher than for PM and FGF-2 (p < 0.001). In HCMEC the sum of assigned stages in cultures
incubated in BM supplemented with VEGF-A, FGF-2 or both factors was in any case higher than in
cultures incubated in PM (Table 3).
The sum of stages of angiogenesis obtained by HDMEC cultivated in the presence of either VEGF-A
or FGF-2 was SVEGF−Aj = 58.6 and SFGF−2j = 57.9, lower than for PM (SPMj = 65.3) and for the cultures
incubated in the presence of both factors, which amount to SVEGF−A+FGF−2j = 64.8 (p < 0.001). The sum
of assigned stages was equal for VEGF-A and FGF-2, respectively for PM and VEGF-A and FGF-2. In
HDMEC the sum of stages of angiogenesis was lower (or almost similar) when cultured in VEGF-A,
FGF-2 or both factors compared to cells cultured in PM (Table 3).
Comparing the sum of assigned stages for HCMEC and HDMEC cultured in the same medium, SPMj was
lower in HCMEC than in HDMEC (p < 0.001), while SVEGF−Aj (p < 0.001) and SVEGF−A+FGF−2j (p < 0.05)
were higher in HCMEC than in HDMEC. SFGF−2j was equal for HCMEC and HDMEC (Table 3).
Table 3
Sums of assigned stages of angiogenesis (S) evaluated in in vitro cultures of human heart (HCMEC) and dermal microvascular
endothelial cells (HDMEC) in positive medium (PM) or in a basic medium supplemented with either VEGF-A or FGF-2, or
both VEGF-A and FGF-2. Four visual fields per well were evaluated and mean values per well together with a mean for each
group are presented. Mean values marked with different letters differ significantly (p < 0.05): a, b – differences between cell
types cultured in the same medium. A, B, C – differences between medium within one cell type. n – number of visual fields
Cell type Well SPM SVEGF-A SFGF-2 SVEGF-A and FGF-2
HCMEC 1 (n = 4) 55 66 59 67
2 (n = 4) 53 65 60 69
3 (n = 4) 55 66 58 69
4 (n = 4) 53 69 62 68
Mean (n = 16) 53.8 ± 2.26aA 66.2 ± 2.37aB 59.6 ± 2.06C 68.1 ± 2.70aB
HDMEC 1 (n = 4) 66 57 57 63
2 (n = 4) 65 58 60 65
3 (n = 4) 65 60 56 65
4 (n = 4) 65 59 59 66
Mean (n = 16) 65.3 ± 3.24bA 58.6 ± 3.10bB 57.9 ± 3.99B 64.8 ± 3.66bA
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3.3. Quantitation of gene expression of VEGF-A and FGF-2 receptors VEGFR-1, VEGFR-2
and FGFR-1
For evaluating the effects of VEGF-A and FGF-2 on angiogenesis in vitro, the gene expression of
their endothelial specific receptors VEGFR-1, VEGFR-2 and FGFR-1 was measured at different time
points, i.e. day 3, 10, 20 and 40 of cultivation. Regarding the course of expression of each receptor, in
both cultures the concentration of VEGFR-1 was higher at day 3 than at day 40. VEGFR-1 showed an
intermittent increase from day 3 to day 10 in HDMEC (Fig. 5). The ratio of VEGFR-2 was approximately
constant at the different times of investigation in both cultures with minor variability at day 10 and 20
(Fig. 5). The concentration of FGFR-1 increased from day 3 to day 40; in HCMEC the highest value was
measured at day 20, whereas in HDMEC the concentration of FGFR-1 increased continuously over the
study (Fig. 5).
Considering the mean amount at all points of investigation (Fig. 6), VEGFR-1 was significantly
down-regulated in HCMEC compared to HDMEC (p < 0.001), whereas the concentration of VEGFR-2
or FGFR-1 showed no differences between HCMEC and HDMEC. Comparison of the ratio of the
both VEGF-receptors within each culture demonstrated that VEGFR-1 was significantly higher than
VEGFR-2 in HDMEC (p < 0.001). In contrast, VEGFR-1 was significantly lower than VEGFR-2 in
HCMEC (p < 0.05).
4. Discussion
Until now, no validated in vitro cell culture system exists in the field of angiogenesis research for pre-
clinical investigation and quantitation of the effects of potentially pro- or antiangiogenic factors. Moreover,
all available in vitro assays are restricted in mutual comparability as they focus on only one phase of the
angiogenic cascade, i.e. migration, proliferation or tube formation [2, 5]. Therefore, we established an
all-in-one assay for quantitation of angiogenesis and antiangiogenesis in vitro that is based on staging
of the angiogenic cascade [3, 4]. In the present study this assay was used to investigate and quantitate
Fig. 5. Gene expression of VEGFR-1, VEGFR-2 and FGFR-1 in human cardiac (HCMEC) and dermal microvascular endothelial
cells (HDMEC) after 3, 10, 20 or 40 days of cultivation. Except for day 40 VEGFR-1 in HDMEC was higher expressed than
VEGFR-1 in HCMEC. Additionally, except for day 40 VEGFR-1 in HDMEC was higher expressed than VEGFR-2 and FGFR-1
in both HDMEC and HCMEC.
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Fig. 6. Gene expression of VEGFR-1, VEGFR-2 and FGFR-1 in human cardiac (HCMEC) and dermal microvascular endothelial
cells (HDMEC). In HDMEC VEGFR-1 was expressed significantly higher than VEGFR-2 as well as VEGFR-1 and VEGFR-2 in
HCMEC (p < 0.001). In HCMEC VEGFR-2 was expressed significantly higher than VEGFR-1 (p < 0.05). FGFR-1 was expressed
not significantly higher in HCMEC than in HDMEC.
angiogenesis in vitro induced by VEGF-A and FGF-2 in two different human microvascular endothelial
cell cultures, derived from the heart (HCMEC) and the skin (HDMEC). For this purpose, VEGF-A and
FGF-2 were either applied separately or in combination to both cultures. Additionally, gene expression of
their blood vessel endothelial specific receptors, i.e. VEGFR-1, VEGFR-2 and FGFR-1, was quantitated
for interpretation and evaluation of the observed effects of the factors on angiogenesis in vitro.
Application of the growth medium provided by the distributor, which was used as positive medium
(PM), as wells as VEGF-A, FGF-2 or their combination led both cultures to run through the defined stages
of angiogenesis in vitro. This means, that cells of both showed chronologically morphological alterations
including elongation, linear arrangement, networking and development of capillary-like structures, which
were taken as the basis for the staging of the angiogenic cascade in vitro. However, one difference was
found in morphology of developing capillary-like structures, which was subjected to the growth factor
used. Incubation of both endothelial cell cultures in VEGF-A led to the development of irregular globular
structures alternating with very thin strand-like structures in stage 5 and 6. This phenomenon could also be
observed in vivo during neonatal development of coronary capillaries in mice lacking 3-integrin, which
modulates VEGF-A induced angiogenesis during the remodelling phase leading to vessel maturation
[41]. Due to the successional overshoot of VEGF-A coronary capillaries failed to mature and continued
to exhibit irregular endothelial thickness [41]. Furthermore, the development of large, irregular and
tortuous vessels in tumours is known to be implicated in high expression levels of VEGF-A [15, 29].
These effects can be explained by the dual role of VEGF-A, acting as an angiogenic but also as a vascular
permeability factor [18, 19].
Not least, this is the reason why application of VEGF-A alone emerged to be insufficient in angiogenesis
therapy [44]. VEGF-A mediates these effects mainly by its receptor VEGFR-2 [17, 32], which was
expressed similarly in HCMEC and HDMEC. Therefore, the development of irregular structures could
be observed in both endothelial cell cultures treated with VEGF-A alone. In opposite, in cultures incubated
either with VEGF-A in combination with FGF-2 or only with FGF-2 regular strand-like structures with
diameters up to 30m developed in stage 5–6. FGF-2 is stated to be an equally potent stimulator of
angiogenesis as VEGF-A [7]. However, the results of the present study show that there might be a
difference in the quality of the angiogenic effects. A comparative study on the effect of FGF-2 on tumour
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growth and angiogenesis in vivo revealed that high expression levels of FGF-2 in the absence of VEGF-A
led to highly vascularised tumours with regular, mature and impermeable vessels [19]. This could be
explained by the fact that FGF-2 lacks an effect on vascular permeability [9, 19].
Quantitation of angiogenesis in vitro induced by VEGF-A and FGF-2 in HCMEC and HDMEC showed
differences in velocity of the course of stages of angiogenesis depending on the growth factor as well as
on the endothelial cell culture used. The slowest run of angiogenesis was observed in HCMEC cultured
in PM. However, this culture showed the fastest run of angiogenesis in the presence of VEGF-A alone as
well as in the presence of VEGF-A in combination with FGF-2. Incubation of HDMEC with VEGF-A
alone resulted in a slower run of angiogenesis in comparison to PM. In addition, the combination of
both growth factors provoked a similar pace of angiogenesis as compared to incubation in PM. Summing
up these findings, it is obvious that application of VEGF-A accelerated angiogenesis in HCMEC, but
not in HDMEC. Considering the expression level of the receptors VEGFR-1 and VEGFR-2, HCMEC
showed a significant lower expression of VEGFR-1 than HDMEC, while the concentration of VEGFR-2
was similar in both cultures. Thus, in HCMEC the expression of VEGFR-1 was significant lower than
the expression of VEGFR-2. These observation allows the conclusion that low expression levels of
VEGFR-1 result in an increase of angiogenic effects of VEGF-A, whereas a high VEGFR-1/VEGFR-2
ratio decelerates angiogenesis in vitro induced by VEGF-A. This phenomenon can be explained by the
angiogenic signalling pathways of VEGFR-1 and VEGFR-2: It is known, that activation of VEGFR-1
inhibits the proangiogenic effects of VEGF-A via VEGFR-2 by sequestering this factor and thus making
it less available to VEGFR-2 [12]. Therefore, VEGFR-1 is suggested to function primarily as a decoy
receptor or as a non-signalling ‘reservoir’ for VEGF-A. Displacing VEGF-A from VEGFR-1 provides
additional VEGF-A available to induce VEGFR-2-mediated angiogenic signalling [27]. The proangio-
genic effects of VEGF-A are essentially provoked by activation of VEGFR-2, which induces the initial
steps of angiogenesis, i.e. migration and proliferation of vascular endothelial cells [7, 32, 37, 38].
Application of FGF-2 showed in both cultures a similar run of angiogenesis. This observation was as
expected, because FGFR-1 was expressed equally in both endothelial cell cultures. However, in compari-
son to cultures incubated in PM, FGF-2 yielded acceleration of angiogenesis in HCMEC and deceleration
of angiogenesis in HDMEC. This might be assigned to the distinct velocity of angiogenesis influenced
by PM in the different cultures. This will be investigated in a further study on analysis of the other growth
factors containing in PM, which was named by the distributor, as well as their corresponding receptors.
In conclusion, the established all-in-one angiogenesis assay was used successfully for quantitation of
angiogenesis in vitro induced by VEGF-A and FGF-2, and the proangiogenic effects of these growth fac-
tors were confirmed. It was further demonstrated that application of VEGF-A alone resulted in incomplete
and aberrant angiogenesis. In addition, the expression of the distinct receptors VEGFR-1 and VEGFR-2
seemed to provoke quantitative effects of VEGF-A on angiogenesis in vitro. Thus, it becomes apparent
that statements on qualitative effects of VEGF-A or FGF-2 on angiogenesis in vitro are comparable
in the different endothelial cultures used. However, quantitative effects are particularly affected by the
corresponding receptors, and therefore, cannot be extrapolated from one to another endothelial cell culture.
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